NICE Recommends Sparsentan for IgA Nephropathy
First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure.
NICE has issued final draft guidance endorsing the use of sparsentan as a treatment option for primary IgA nephropathy in adults presenting with significant proteinuria. This recommendation follows clinically significant findings from the phase-III PROTECT trial.
In essence, NICE concluded that sparsentan demonstrates value and efficacy, making it a viable treatment choice within the National Health Service (NHS). The guidance stipulates that treatment must commence within 90 days from the final publication, ensuring timely access for patients.
Professor Jonathan Barratt, a recognized expert in renal medicine, expressed optimism regarding NICE's decision. He noted that effective treatments like sparsentan are critical for improving patient outcomes, particularly given the alarming rates at which IgA nephropathy can progress to kidney failure.
IgA nephropathy occurs when faulty immunoglobulin A deposits accumulate in the kidney's glomeruli, leading to inflammation and deterioration of kidney function. This often results in symptoms such as blood and protein in the urine, with persistent proteinuria significantly correlating with progression to kidney failure.
Despite its classification as a rare disease, IgA nephropathy is the most prevalent type of primary glomerular disease, affecting thousands of adults. Studies show a grim prognosis for those who don’t receive adequate management, with a notable percentage facing kidney failure within a decade of diagnosis.
The KDIGO guidelines indicate that patients showing persistent protein excretion above 1 g/day require close monitoring and potential therapeutic intervention to mitigate the risk of chronic kidney disease progression.
In light of the NICE recommendation, Dr. Vinicius Gomes De Lima from CSL Vifor emphasized the importance of bringing sparsentan to patients in need, highlighting the urgent medical necessity for effective treatment options in this patient population.
CSL Vifor is planning to launch sparsentan in the UK in the latter part of 2025, following a successful marketing authorization by the relevant health authorities.
About Sparsentan
Sparsentan, developed by Travere Therapeutics, has been recognized for its unique dual-action properties that target both endothelin A receptors and angiotensin II subtype 1 receptors. This groundbreaking treatment provides a novel approach that is non-immunosuppressive, presenting an innovative therapeutic avenue for managing IgA nephropathy.
The efficacy of sparsentan was substantiated during the PROTECT trial, which compared its performance against irbesartan in adult patients affected by IgA nephropathy. The study illustrated significant reductions in proteinuria among those treated with sparsentan, confirming its potential to improve patient management outcomes.
As CSL Vifor anticipates the successful rollout of sparsentan, the company remains focused on fulfilling its commitment to enhancing patient care in renal health.
Frequently Asked Questions
What is sparsentan used for?
Sparsentan is used as a treatment for IgA nephropathy, aiming to reduce proteinuria and improve kidney health.
Who developed sparsentan?
Sparsentan was developed by Travere Therapeutics and is commercially available by CSL Vifor in certain regions.
What are the benefits of sparsentan?
The drug offers a non-immunosuppressive option that targets two receptors involved in kidney disease progression, potentially improving patient outcomes.
When will sparsentan be available in the UK?
Sparsentan is expected to launch in the UK in the second half of 2025.
What is IgA nephropathy?
IgA nephropathy is a progressive kidney disease characterized by deposits of immunoglobulin A in the kidneys, leading to symptoms such as proteinuria and eventual kidney damage if untreated.
